HPV vaccines: Translating immunogenicity into efficacy
Currently available human papillomavirus (HPV) vaccines are very successful at preventing persistent HPV infection and premalignant cervical lesions. In part due to the unique aspects of HPV immunogenicity and high levels of efficacy no immune correlate has been identified for HPV vaccination. Serum...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2016-06, Vol.12 (6), p.1403-1405 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1405 |
|---|---|
| container_issue | 6 |
| container_start_page | 1403 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 12 |
| creator | Turner, Taylor B. Huh, Warner K. |
| description | Currently available human papillomavirus (HPV) vaccines are very successful at preventing persistent HPV infection and premalignant cervical lesions. In part due to the unique aspects of HPV immunogenicity and high levels of efficacy no immune correlate has been identified for HPV vaccination. Serum neutralizing antibodies are used to measure vaccine response, but their role as a correlate has not been verified, and this theory fails to explain the prevention of HPV related non-mucosal lesions. Identifying a true correlate would aid in future work in this area but will be difficult in the setting of a highly efficacious vaccine. |
| doi_str_mv | 10.1080/21645515.2015.1103936 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4964637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1797254347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-87c7bb177d3aa528af691e088b28e3a4ea62d2bd6cf8df7a346267050b06331d3</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMoWtSfoMzSTTXvTF2IUnyBoAsVd-FOJqmRmaQm00r_vVNai268i9xLcs654UPoiOBTgkt8RonkQhBxSnF_EILZiMktNFjeD4Xgb9ubmYg9dJjzB-5LYcql3EV7VApClaQDJO-eXos5GOODzefFc4KQG-h8mBS-bWchTmzwxneLwocuFtY5b8AsDtCOgybbw3XfRy8318_ju-HD4-39-OphaLgsu2GpjKoqolTNAAQtwckRsbgsK1paBtyCpDWtamlcWTsFjEsqFRa4wpIxUrN9dLHKnc6q1tbGhi5Bo6fJt5AWOoLXf1-Cf9eTONd8JLlkqg84WQek-DmzudOtz8Y2DQQbZ1kTNVJUcMaXUrGSmhRzTtZt1hCsl9j1D3a9xK7X2Hvf8e8_blw_kHvB5Urgg4upha-Ymlp3sGhicj1w47Nm_-_4Br0Ikbk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797254347</pqid></control><display><type>article</type><title>HPV vaccines: Translating immunogenicity into efficacy</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Turner, Taylor B. ; Huh, Warner K.</creator><creatorcontrib>Turner, Taylor B. ; Huh, Warner K.</creatorcontrib><description>Currently available human papillomavirus (HPV) vaccines are very successful at preventing persistent HPV infection and premalignant cervical lesions. In part due to the unique aspects of HPV immunogenicity and high levels of efficacy no immune correlate has been identified for HPV vaccination. Serum neutralizing antibodies are used to measure vaccine response, but their role as a correlate has not been verified, and this theory fails to explain the prevention of HPV related non-mucosal lesions. Identifying a true correlate would aid in future work in this area but will be difficult in the setting of a highly efficacious vaccine.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2015.1103936</identifier><identifier>PMID: 26512762</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Biomarkers - analysis ; Female ; Human papilloma virus vaccine ; Humans ; immune correlate ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - immunology ; Treatment Outcome</subject><ispartof>Human vaccines & immunotherapeutics, 2016-06, Vol.12 (6), p.1403-1405</ispartof><rights>2016 Taylor & Francis 2016</rights><rights>2016 Taylor & Francis 2016 Taylor & Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-87c7bb177d3aa528af691e088b28e3a4ea62d2bd6cf8df7a346267050b06331d3</citedby><cites>FETCH-LOGICAL-c468t-87c7bb177d3aa528af691e088b28e3a4ea62d2bd6cf8df7a346267050b06331d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964637/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964637/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26512762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turner, Taylor B.</creatorcontrib><creatorcontrib>Huh, Warner K.</creatorcontrib><title>HPV vaccines: Translating immunogenicity into efficacy</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Currently available human papillomavirus (HPV) vaccines are very successful at preventing persistent HPV infection and premalignant cervical lesions. In part due to the unique aspects of HPV immunogenicity and high levels of efficacy no immune correlate has been identified for HPV vaccination. Serum neutralizing antibodies are used to measure vaccine response, but their role as a correlate has not been verified, and this theory fails to explain the prevention of HPV related non-mucosal lesions. Identifying a true correlate would aid in future work in this area but will be difficult in the setting of a highly efficacious vaccine.</description><subject>Biomarkers - analysis</subject><subject>Female</subject><subject>Human papilloma virus vaccine</subject><subject>Humans</subject><subject>immune correlate</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Vaccines - immunology</subject><subject>Treatment Outcome</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEUhYMoWtSfoMzSTTXvTF2IUnyBoAsVd-FOJqmRmaQm00r_vVNai268i9xLcs654UPoiOBTgkt8RonkQhBxSnF_EILZiMktNFjeD4Xgb9ubmYg9dJjzB-5LYcql3EV7VApClaQDJO-eXos5GOODzefFc4KQG-h8mBS-bWchTmzwxneLwocuFtY5b8AsDtCOgybbw3XfRy8318_ju-HD4-39-OphaLgsu2GpjKoqolTNAAQtwckRsbgsK1paBtyCpDWtamlcWTsFjEsqFRa4wpIxUrN9dLHKnc6q1tbGhi5Bo6fJt5AWOoLXf1-Cf9eTONd8JLlkqg84WQek-DmzudOtz8Y2DQQbZ1kTNVJUcMaXUrGSmhRzTtZt1hCsl9j1D3a9xK7X2Hvf8e8_blw_kHvB5Urgg4upha-Ymlp3sGhicj1w47Nm_-_4Br0Ikbk</recordid><startdate>20160602</startdate><enddate>20160602</enddate><creator>Turner, Taylor B.</creator><creator>Huh, Warner K.</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160602</creationdate><title>HPV vaccines: Translating immunogenicity into efficacy</title><author>Turner, Taylor B. ; Huh, Warner K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-87c7bb177d3aa528af691e088b28e3a4ea62d2bd6cf8df7a346267050b06331d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Biomarkers - analysis</topic><topic>Female</topic><topic>Human papilloma virus vaccine</topic><topic>Humans</topic><topic>immune correlate</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Vaccines - immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turner, Taylor B.</creatorcontrib><creatorcontrib>Huh, Warner K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turner, Taylor B.</au><au>Huh, Warner K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HPV vaccines: Translating immunogenicity into efficacy</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2016-06-02</date><risdate>2016</risdate><volume>12</volume><issue>6</issue><spage>1403</spage><epage>1405</epage><pages>1403-1405</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Currently available human papillomavirus (HPV) vaccines are very successful at preventing persistent HPV infection and premalignant cervical lesions. In part due to the unique aspects of HPV immunogenicity and high levels of efficacy no immune correlate has been identified for HPV vaccination. Serum neutralizing antibodies are used to measure vaccine response, but their role as a correlate has not been verified, and this theory fails to explain the prevention of HPV related non-mucosal lesions. Identifying a true correlate would aid in future work in this area but will be difficult in the setting of a highly efficacious vaccine.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>26512762</pmid><doi>10.1080/21645515.2015.1103936</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2016-06, Vol.12 (6), p.1403-1405 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4964637 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Biomarkers - analysis Female Human papilloma virus vaccine Humans immune correlate Papillomavirus Infections - epidemiology Papillomavirus Infections - prevention & control Papillomavirus Vaccines - immunology Treatment Outcome |
| title | HPV vaccines: Translating immunogenicity into efficacy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HPV%20vaccines:%20Translating%20immunogenicity%20into%20efficacy&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Turner,%20Taylor%20B.&rft.date=2016-06-02&rft.volume=12&rft.issue=6&rft.spage=1403&rft.epage=1405&rft.pages=1403-1405&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2015.1103936&rft_dat=%3Cproquest_pubme%3E1797254347%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797254347&rft_id=info:pmid/26512762&rfr_iscdi=true |